Company News » Federman & Sherwood Investigates CytRx Corporation for Possible Violations of Federal Securities LawsBusiness Wire - September 16, 2014, 15:36 GMT
The law firm of Federman & Sherwood has initiated an investigation into CytRx Corporation (NASDAQ:CYTR) with respect to possible violations of federal securities laws. CytRx Corporation (“CytRx”) is a pharmaceutical research and development company headquartered in Los Angeles, California. Federman & Sherwood’s investigation focuses on allegations that CytRx hired a promoter, The DreamTeam Group,
Company News » Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More InformationBusiness Wire - September 15, 2014, 19:24 GMT
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., announce that on June 17, 2014, the United States District Court for the Central District of California appointed KSF as sole lead counsel in Chen v. CytRx Corporation, et al., 2:14-cv-01956-GHK, a securities fraud class action
Company News » Zeldes & Haeggquist, LLP Continues Investigation of CytRx Corporation
Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into possible violations of the federal securities laws and other violations of law by certain officers and directors at CytRx Corporation (“CytRx” or the “Company”) (NASDAQ:CYTR) . CytRx is a pharmaceutical research and development company headquartered in Los Angeles,
Company News » CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced SarcomasBusiness Wire - September 9, 2014, 10:02 GMT
CytRx Corporation (NASDAQ:CYTR) , a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus ifosfamide/mesna as a first-line treatment in subjects with various sarcomas. Aldoxorubicin is CytRx’s modified version of the widely-used
Company News » CytRx Updates Presentation Time at Aegis 2014 Healthcare & Technology ConferenceBusiness Wire - September 5, 2014, 10:01 GMT
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced a change in the Company’s presentation time at the at Aegis 2014 Healthcare & Technology Conference. President and CEO Steven A. Kriegsman and Vice President of Business Development David Haen will present on Friday, September 12th at 10:45am Pacific Time.
Company News » CytRx to Present at Upcoming Investor Conferences in New York City and Las VegasBusiness Wire - September 2, 2014, 10:05 GMT
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that President and CEO Steven A. Kriegsman and Vice President of Business Development and Investor Relations David Haen will present at the following upcoming investor conferences: 16th Annual Rodman & Renshaw Healthcare Conference on Tuesday, September 9, 2014 at 12:05 p.m.